Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
@HereforHemo, I really can’t disagree with a single word that you have said.
The CLN was a calamity to the share price.
To me, that question is not even up for discussion.
And that was the reason, why I sold a significant amount of my shares in Hemogenyx some time after I heard about the CLN, and with a loss.
I really do not like CLN’s.
Back then, I was afraid that Hemogenyx could be taken over. If I remember correctly, then the CLN’s could amount to 3 times the number of shares that Hemogenyx had in circulation at that point, if they were to be cashed in under the most favorable conditions.
Time went by, and my fear did not prove to be correct, and so I started to add to my holding again. And I have continued to do so, on the way down. Always thinking it does not get much cheaper then this (boy, has I wrong on many occasions) hence why, like so many others here, I sit on a huge loss, should I choose to sell up at this stage.
I wont however. Call it stubbornness, faith, hope or whatever you want.
It just so happens, that I like the way Mr. Sandler conduct himself. And I might be reading to much into it, because this is the way I want to see it.
But I much prefer to be invested in a company with a CEO who does not feel like spending money on RNS’ about everything and nothing in the hope to increase the share price.
To me it is integrity, when you want the results to speak for themselves. Instead of loads of RNS’ about nothing of substance just with the hope of increasing the share price.
And since no one will accuse Mr. Sandler of that, I feel I am in good hands here.
Added bonus, I feel he has listened to the critique and increased the PR with interviews and so forth, maybe not successfully from the share price point, but I get to know him a bit better each time and I appreciate that.
@JustHereForHemo, as with HereforHemo, I can’t really disagree with a word you say (and generally I don’t, please keep your often well researched and thoughtful posts coming)
But I liked your take on Minty better a couple of day’s ago, when you talked about how things might not have worked out as he expected and suddenly found himself in a different situation then expected.
It gave me things for thought and I must admit, had I been in a situation where I had lend out millions and expected to get them back in a short time, with a very good return, and then the deal falls through.
Well then I might have done exactly what Minty did. Thinking that any true investor would get their investment back and they would get the opportunity to buy in cheaper as well.
And that is why, annoying as it is to sit with a way to high loss for my liking, I am still chuffed to bits.
Had the share price been trading in the 5-7 pence ratio, I would not have the amount of shares I do.
So, I am happy because there was a fantastic opportunity and I have been able to take advantage.
Great Post socialist, I do agree with HFH though about the CLNs and placing. It should have been done MUCH sooner at a much higher SP, and without the rich individuals who took the bulk of the placing and dumped before the shares were ever listed. I am in complete support of the science, the work, but mistakes were made in the financial side right to the very end of the CLNs. I had a list of people who would have taken part in the placing, very few got a call to actually take part, all of them would have held. But preference was given to a lier who dumped and screwed us all. But.....
Its done, they have the cash, they know mistakes were made and they won't repeat them. Now we are within smelling distance of clinical trials and this pathetic SP is a massive buying opportunity.
I am for sure in Camp 2, but not without regrets along the way!
Everyone is here to turn a profit. Those who participate in placings are just handed a 25% discount that enables them to flip their shares earlier. The problem with Hemo’s placement was that firstly it should have been at 7p and not 1.5p and secondly it wasn’t offered as an open offer to existing shareholders (with the exception of one or two), it was offered to select wealthy individuals who had already sold out of HEMO on the spike with a healthy profit and who immediately sold again, taking their 25% profit and crashing the SP. So if you think Vlad and the BOD have done a good job with financing the company through the above and the disastrous CLN agreement I think you’ll find you’re in the minority.
If you participate in a placing and all the money goes to the company (minus expenses) then you could possibly claim a high moral ground and say that you are doing it to support science. And that you do not care about the share price. And the statement would carry some merit.
For the rest of us, it becomes near impossible to claim that, as we are just buying from the next John Doe, and no money is landing in the coffers of Hemogenyx as a result of that transaction.
So it would not be unfair to conclude, that most of us are here to turn a profit.
Hence the headline: What camp are you in when it comes to turning a profit.
1. You wish you had never bought into Hemogenyx or even better then that, would be to never have heard of the company.
2. You see the current low price as an opportunity to get a high number of shares, expecting them to multiply several times over on good news or even better, on good clinical results.
Whatever camp you’re in, I am sure no one is enjoying sitting on a 30-40-50-60% loss.
Could Dr. Vladislav Sandler have done things differently: YES
Should he have done things differently: NO
Okay, so that last answer is a bit provocative and deliberately so.
But from my personal point of view, had the price not dropped down to sub 2 pence level, there is no way on earth that I would have been able to accumulate the number of shares that I have today.
I have managed to multiply the dream target that I had this time last year, many times over.
So, despite a huge loss, I am chuffed to bits.
This is a buying opportunity. And has been for a long time.
And I, for purely selfish reasons, do not mind if it stays here a little while longer, until another one of my shares comes good, and I can move the profit over here, at these prices.
So, I am very happy with the RNS’ that we have had in 2021 and Dr. Sandler's communication and not least his priorities.
I will much rather have a man at the helm who focuses on what really matters.
Create treatments that works.
If, he and his team are successful in this matter, then the money will follow automatically (at least that is my expectation)
In 2021 the foundation has been laid to the clinical trial that we will soon hear more about.
I am excited about the outcome. If it is good, then everybody is a winner, even the one who I will be selling a part of my allocation to, because it will just rise and rise (with setbacks along the way)